Tirzepatide
Dual GIP / GLP-1 agonist · 39 aa. The dual incretin studied across the SURMOUNT Phase III trial program.
Research-grade peptides, verified by an independent U.S. lab — every lot tested to ISO 17025 standards for identity and purity, with the Certificate of Analysis on file for every order. Research-grade peptides. Independently U.S. lab-tested. COA with every order.
≥ 99% pure
HPLC + mass-spec on every lot
Independently tested
ISO/IEC 17025 accredited lab
Same-day shipping
Order by 5pm ET · California warehouse
Research protocols cited from peer-reviewed sources
The peptides researchers reorder most — every lot is identity- and purity-confirmed twice, the second pass by an independent, US-based ISO/IEC 17025 lab, then traced from synthesis to the vial in your hand.
Dual GIP / GLP-1 agonist · 39 aa. The dual incretin studied across the SURMOUNT Phase III trial program.
GLP-1 receptor agonist · 31 aa. The GLP-1 agonist characterized across the STEP Phase III trial program.
GIP / GLP-1 / Glucagon triple-agonist · 39 aa. The investigational triple agonist studied in Phase II metabolic-endpoint trials.
Pentadecapeptide · 15 aa, gastric origin. The most-cited compound in our Tissue & Connective Repair coverage.
Nicotinamide adenine dinucleotide · coenzyme. The redox cofactor studied across cellular-energy and aging pathways.
GH-releasing pentapeptide · 5 aa. Selective ghrelin-receptor agonist without the cortisol/prolactin spike.
Short-acting GHRH analog · 29 aa. The mod-GRF(1‑29) form with the ~30-minute plasma half-life.
Copper tripeptide · 3 aa. The skin-remodeling copper peptide in our Aesthetics coverage.
Thymosin β4 fragment · 7 aa active core. Actin-binding peptide with a deep cardiac-repair preclinical literature.
Our US-based partner lab, an ISO 17025–accredited facility, runs identity, purity, endotoxin, microbial, and contaminant assays on every batch. This is a secondary screening aimed at ensuring we offer the highest-quality research product.